{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"24.45","upperLimit":"50.66","value":"36.8"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"57"}],"units":"Participants"}],"description":"Percentage of participants without any RBC transfusion during any consecutive 8 weeks (56 days) starting from Study Day 1 until subsequent anti-cancer therapy if any were reported. Study Day 1 is defined as the day of the first dose for participants enrolled in Phase 2. The 95% confidence interval (CI) was calculated using Clopper-Pearson method. Percentages were rounded off to the nearest single decimal place.","dispersionType":"95% Confidence Interval","groups":[{"description":"Imetelstat sodium administered IV, at a starting dose of 7.5 mg/kg, every 4 weeks (on a 28-day cycle) until death, lost to follow-up, withdrawal of consent, or study termination whichever occurs first. Dose escalation to 9.4 mg/kg was allowed before Protocol Amendment 2.","id":"OG000","title":"Phase 2: Imetelstat Sodium"}],"paramType":"NUMBER","populationDescription":"Phase 2: All Treated Analysis Set included all participants who received at least one dose of study drug.","reportingStatus":"POSTED","timeFrame":"Up to 5 years in Phase 2","title":"Phase 2: Percentage of Participants Without Any Red Blood Cell (RBC) Transfusion During Any Consecutive 8-Weeks Period (All Participants)","type":"PRIMARY","unitOfMeasure":"percentage of participants"}